TORVAST 20 TABLETS

Indications

• Primary hypercholesterolemia
• Mixed dyslipidemia
• Prevention of cardiovascular disease
• Hyperlipoproteinemia type IIa and IIb

Dosage

Children: Refer to BNF for Children for specific pediatric dosing information, as doses may vary based on age, weight, and clinical condition.

Adults: Refer to BNF for specific dosing guidance based on individual patient needs and response to therapy. Generally, the starting dose may range from 10 to 80 mg once daily.

Mechanism of action

Torvast acts as a competitive inhibitor of HMG-CoA reductase, the enzyme responsible for converting HMG-CoA to mevalonate, a precursor in the cholesterol synthesis pathway. This inhibition leads to decreased cholesterol production and increased uptake of LDL cholesterol from the bloodstream by the liver, thereby lowering serum LDL cholesterol levels.

Pharmacodynamics

The pharmacodynamic effects of Torvast include its ability to significantly reduce levels of total cholesterol, LDL cholesterol, and triglycerides, while modestly increasing HDL cholesterol levels. The drug's lipid-lowering effects are dose-dependent and can lead to a reduction in the risk of atherosclerosis and cardiovascular events.

Pharmacokinetics

Torvast is well-absorbed following oral administration, with peak plasma concentrations occurring within 1 to 2 hours. It undergoes extensive hepatic metabolism, primarily via the cytochrome P450 enzyme system. The half-life of Torvast is approximately 14 hours, allowing for once-daily dosing. Elimination occurs predominantly through the feces, with less than 10% excreted in urine.

Pregnancy

There is limited data on the use of torvast during pregnancy. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known if torvast is excreted in human milk. Caution should be exercised when administering to nursing women.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.